Technology evaluation: TroVax, Oxford BioMedica.
TroVax, a gene-based tumor vaccine that uses a poxvirus vector to deliver the tumor antigen gene 5T4, is under development by Oxford BioMedica for the potential treatment of cancer. TroVax is undergoing phase II clinical trials.
Academy of Sciences of the Czech Republic, Institute of Molecular Genetics, Flemingovo nam 2, Prague 6, CZ 16637, Czech Republic. reinis@img.cas.cz
Milan
M
Reinis
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D019496:Cancer Vaccines / Q000009:adverse effects* / Q000378:metabolism* / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D051379:Mice; D013329:Structure-Activity Relationship; D019444:Vaccines, DNA
D000970:Antineoplastic Agents; D019496:Cancer Vaccines; C504058:TroVax; D019444:Vaccines, DNA